Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma
Jennifer L. Crombie(Dana-Farber Cancer Institute), Iris Isufi(Yale University), Saurabh Dahiya(Stanford University), Alex F. Herrera(City of Hope), M. Pasquini(Medical College of Wisconsin), Sagar S. Patel(University of Utah), Avyakta Kallam(City Of Hope National Medical Center), Fei Fei Liu(Bristol-Myers Squibb (United States)), David Bernasconi(Bristol-Myers Squibb (United States)), Bradley D. Hunter(Intermountain Healthcare), Ogechukwu Egini(Rutgers, The State University of New Jersey), Dongjin Lee(Korea Advanced Institute of Science and Technology), Abu-Sayeef Mirza(Moffitt Cancer Center), Debasmita Roy(Bristol-Myers Squibb (United States)), Soyoung Kim(Medical College of Wisconsin), Krish Patel(Sarah Cannon), Swetha Kambhampati Thiruvengadam(City Of Hope National Medical Center), Patrick M. Reagan(University of Rochester Medical Center), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Mehdi Hamadani(Medical College of Wisconsin), Mazyar Shadman(Fred Hutch Cancer Center), Matthew A Lunning(University of Nebraska Medical Center), Catherine J. Lee(University of Utah), Matthew J. Frigault(Massachusetts General Hospital), María Silvina Odstrcil Bobillo(University of Utah)
Cited by 1
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study
|The Lancet Rheumatology|2020|309
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation
|Journal of Clinical Oncology|2016|187